CLRB

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m.

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in  Relapsed/Refractory Multiple Myeloma

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in  Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time.

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing efforts.